CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

Hematological Malignancy Clinical Trial

Official title:

CAR-T Cellular Therapy for B Cell Malignancies Involved in Central Nervous System

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04287309
• Other study ID #: 19-002
• Status: Recruiting
• Start date: February 28, 2020
• Est. completion date: February 28, 2023

Study information

• Verified date: February 2020
• Source: Zhejiang University
• Contact: He Huang, PhD
• Phone: 13605714822
• Email: huanghe[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-line hematological malignancy involved in CNS. 20 patients were enrolled. Primary objective is to explore the safety. The secondary objective is to explore the efficacy.

Description:

This is a single arm, open-label, single-center study. This study is indicated for relapsed or refractory CD19+ B-line hematological malignancy involved in CNS. All together 20 patients were enrolled. Primary objective is to explore the safety including the complication of cytokine release syndrome, CRES, pancytopenia and infection. The secondary objective is to explore the efficacy. We will also detect CAR-T cell expansion dynamics in blood and cerebral fluid and compare the difference.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: February 28, 2023
• Est. primary completion date: February 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 75 Years

Eligibility

Inclusion Criteria:

1.Male or female aged = 3 and <70 years old; 2.Histologically confirmed diagnosis of CD19+ B cell malignancies involved in CNS 3.Relapsed or refractory CD19+ B cell malignancies 4.total bilirubin = 51umol/L, ALT and AST = 3 times of upper limit of normal, creatinine = 176.8umol/L; 5.Echocardiogram shows left ventricular ejection fraction (LVEF) = 50%; 6.No active infection in the lungs, blood oxygen saturation by sucking air is = 92%; 7.Estimated survival time = 3 months; 8.ECOG performance status 0 to 2; 8.Patients or their legal guardians volunteer to participate in the study and sign the informed consent.

Exclusion Criteria:

1. Patients with hereditary syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome;

2. extensive involvement of gastrointestinal lymphoma;

3. radiotherapy, chemotherapy and monoclonal antibody within 1 week before screening;

4. Have a history of allergy to any of the components in the cell products;

5. According to the New York heart association (NYHA) cardiac function classification criteria, Subjects with grade III or IV cardiac insufficiency;

6. Myocardial infarction, cardioangioplasty or stenting, unstable angina pectoris, or other severe cardiac diseases within 12 months of enrollment;

7. Severe primary or secondary hypertension of grade 3 or above (WHO Hypertension Guidelines, 1999);

8. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;

9. Patients with severe active infections (excluding simple urinary tract infection and bacterial pharyngitis).

10. Indwelling catheters in vivo (e.g. percutaneous nephrostomy, Foley catheter, bile duct catheter, or pleural/peritoneal/pericardial catheter). Ommaya storage, dedicated central venous access catheters such as Port-a-Cath or Hickman catheters are allowed;

11. History of other primary cancer, except for the following conditions:

1. Cured non-melanoma after resection, such as basal cell carcinoma of the skin;

2. Cervical cancer in situ, localized prostate cancer, ductal cancer in situ with disease-free survival = 2 years after adequate treatment;

12. Patients with graft-versus-host disease (GVHD);

19.Prior immunizations with live vaccine 4 weeks prior to screening; 13.History of alcoholism, drug abuse or mental illness; 14.Concurrent therapy with systemic steroids within 1 week prior to screening, except for the patients recently or currently receiving inhaled steroids; 15.Patients who have participated in any other clinical studies within 2 weeks prior to screening; 16.pregnant and breast-feeding women and the subjects who are fertile and unable to take effective contraceptive measures (regardless of the gender); 17.Any situations that the investigator believes may increase the risk of patients or interfere with the results of study.

Related Conditions & MeSH terms

• Hematological Malignancy
• Neoplasms

Intervention

Other:
• CAR-T cells
CD19 targeted CAR-T treatment

Locations

Country	Name	City	State
China	the First Affiliated Hospital,School of Medicine, Zhejiang University	Hangzhou	Zhejiang
China	The First Hospital of Zhejiang Medical Colleage Zhejiang University	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events that related to treatment	Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)	2 years
Secondary	The response rate of CAR-T treatment in patients with relapse/refractory B cell malignancies involved in CNS that treated by CD19 CAR-T cells therapy	The response rate of BCMA CAR-T treatment will be recorded and assessed according to WHO criteria	6 months